Virus News and Research

Latest Virus News and Research

Brain can act as a hiding place for HIV virus: Study

Studies of the spinal fluid of patients given anti-HIV drugs have resulted in new findings suggesting that the brain can act as a hiding place for the HIV virus. Around 10% of patients showed traces of the virus in their spinal fluid but not in their blood.

23 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Hepatitis E vaccine successful in clinical trial: Study

In a Clinical trial in China, a vaccine has been found to protect against Hepatitis E. Hepatitis E virus, usually spread via contaminated food and faeces usually runs its course before the patient recovers. However it can cause severe illness in elderly people and has a mortality rate of 1 to 3 percent. It can also kill 5 to 25 percent of affected pregnant women and those who survive can suffer high rates of miscarriage. Around a third of the world's population have been infected by the virus say researchers.

22 Aug 2010

HHS Secretary releases review of new federal approach to medical countermeasures

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures. The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs reviews the process and makes recommendations for a better approach.

21 Aug 2010

HHS unveils $1.9B strategy to better prepare for biological threats

"Acknowledging that the development of medical countermeasures against bioterrorism threats and pandemic flu is lagging, [U.S.] federal authorities Thursday announced a $1.9 billion makeover of the system for identifying and manufacturing drugs and vaccines for public-health emergencies," Tribune Company/Seattle Times reports.

21 Aug 2010

Scientists identify compound to treat Chagas' disease

A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.

21 Aug 2010

CDC says teen vaccination rates up but should go higher

The Wall Street Journal writes about vaccination rates among teens: "The CDC says more teenagers got their recommended immunizations last year, but that there's room for improvement — for example, only 27% of teenage girls received the recommended three doses of human papilloma virus (HPV) vaccine.

21 Aug 2010

Cubist Pharmaceuticals ranked 31st on FORTUNE's 2010' 100 Fastest-Growing Companies' list

Cubist Pharmaceuticals, Inc. today announced it has been ranked 31st on FORTUNE's 2010 "100 Fastest-Growing Companies" list and the top pharmaceutical company. In the "Profit Growth" subgroup Cubist ranked 21st. The magazine will be on the newsstands on August 23 and the full list is available today online.

21 Aug 2010

Combination of 2 FDA approved drugs eliminate HIV infection

Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV.

21 Aug 2010

Chicago-based pasteurized eggs producer increases production following recall of salmonella-infected eggs

Chicago-based National Pasteurized Eggs today ramped up production of its industry-leading salmonella-free Davidson's Safest Choice Pasteurized Shell Eggs as federal health officials expanded the recall of eggs linked to salmonella enteritidis to 380 million.

20 Aug 2010

Research may puzzle out HIV transmission by sexual contact

The virus that causes AIDS may undergo changes in the genital tract that make HIV-1 in semen different than what it is in the blood, according to a study led by researchers from the University of North Carolina at Chapel Hill.

20 Aug 2010

General Physics to provide AAR/IP to gauge overall response to H1N1 outbreak

Global performance improvement solutions provider General Physics Corporation, a subsidiary of GP Strategies Corporation, has been selected by the Maryland Department of Public Health and Mental Hygiene to provide an After Action Report/Improvement Plan for the 2009 response to the H1N1 virus. GP will collect data from public health entities in order to gauge the overall response to the H1N1 outbreak and lessons learned, for DHMH to evaluate and consider for future pandemic response.

19 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

Innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy describes an innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus.

19 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Study outlines recommendations for prevention, management of health epidemics

A new study reveals that the oil and gas industry supply chain which includes oil companies, contractors and sub-contractors does not perceive the full extent of the risks that HIV/AIDS, tuberculosis (TB) and malaria pose to its workforce, productivity and profitability. The study conducted by management consulting firm Booz & Company in partnership the Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria (GBC) outlines why the oil and gas industry should improve its understanding of the hazards posed by these three epidemics and makes ten recommendations for how to make health a priority.

19 Aug 2010

Scientists suggest immunization against oncogenic herpesviruses can prevent cancer

Viruses that can invade host cells, initiate cancer and then flee fromb their own trail of destruction could be stopped in their tracks, say researchers writing in the September issue of the Journal of General Virology.

19 Aug 2010

Reuters examines measles outbreaks in Africa

Reuters reports on how some health experts worry that growing complacency about the threat of measles in Africa is contributing to "some of the largest and most deadly outbreaks in years." Worldwide, "[a]bout 164,000 people died from measles in 2008, down 78 percent from 733,000 in 2000, according to the Measles Initiative," Reuters reports, adding that "UNICEF fears the combined effect of decreased political and financial commitment to measles could reverse the gains, resulting in an estimated 1.7 million measles-related deaths globally between 2010 and 2013."

19 Aug 2010

Rush University Medical Center tests new drug therapy for West Nile fever

Neurological and infectious disease experts at Rush University Medical Center are testing a new drug therapy for the treatment of individuals with West Nile fever or suspected central nervous system infection due to the West Nile virus. Rush is the only site in the Midwest enrolling patients into the $50 million dollar, NIH-funded, Phase II clinical trial called PARADIGM.

18 Aug 2010

Uniform adoption of national HIV quality performance measures needed

To improve the quality of HIV care and treatment nationwide, 17 measures such as screening and prevention for infections and monitoring of antiretroviral therapy should be adopted uniformly, according to a work group led by a Kaiser Permanente researcher.

18 Aug 2010